Award

Portfolio Data

Icon: back arrowBack to Award Search

Leadless Pacemaker Betavoltaic Power Source

Awardee

CITY LABS, INC.

12217 SW 131ST AVE
MIAMI, FL, 33186-6401
USA

Award Year: 2024

UEI: LD55BB3D8EM7

HUBZone Owned: No

Woman Owned: No

Socially and Economically Disadvantaged: Yes

Congressional District: 26

Tagged as:

SBIR

Phase II

Seal of the Agency: HHS

Awarding Agency

HHS

Branch: NIH

Total Award Amount: $251,156

Contract Number: 1SB1HL174312-01A1

Agency Tracking Number: SB1HL174312

Solicitation Topic Code: NHLBI

Solicitation Number: PAR23-219

Abstract

PROJECT SUMMARY Lithium-based batteries have reached a technological limit of ~0.6 cc for use in leadless cardiac pacemaker (LCP) applications and a useful life of only 7-10 years1. The 0.6 cc volume comprises over 60% of the LCP’s total volume and is a technological miniaturization limit to LCPs. City Labs is developing a small betavoltaic power source with sufficient current density to power a pulse generator circuit. The battery’s volume can be as small as 0.1 cc, while providing a consistent ≥3.8 μW for 20 years. This size reduction would allow for an LCP to be implanted in the atria, permitting multi-chamber leadless pacing for patients previously relegated to conventional pacemakers. Furthermore, a decrease in size grants both the manufacturer of delivery catheters and the clinicians operating them a higher degree of flexibility, both in developing the device design process and implantation protocol, even permitting multiple LCPs in a single chamber. A longer-lived pacemaker also expands the potential use of LCPs to younger demographics. LCPs’ retrieval is difficult, so they are often used in patients who are not projected to outlive the device2,3. We will be designing and manufacturing a polyimide-based package that will be biocompatible and safe. It will fit in a leadless pacemaker’s titanium housing, providing double encapsulation. The project goal is to make the most reliable polyimide device configuration and manufacturing approach for transition to market approval with the pacemaker manufacturing partner. We propose a research and development optimization of industrial production methods necessary to ensure consistent and controlled scale-up manufacturing according to recognized quality standards and FDA requirements. City Labs has developed and utilized helium generation and leak models for the predictive design of packaging and components indicative of measured values. Model and measured data will undergo rigorous tuning and analysis under this CRP to ensure adequate predictability and tolerance for diffusion rates in a polyimide package. Furthermore, all packages will be tested to ensure they meet the designed leak rate. The final optimization of the prototype entails the sealing of end caps, feedthroughs, wall thickness, and leak rates associated with components and sealing processes. We will quantify the component and sealing process leak rates with a helium leak detector. This will enable us to produce a package, with controlled hermeticity and minimized volume, from components fabricated in-house, like additively manufactured end caps and specialized electrical contacts. To fabricate and seal such polyimide components, we will acquire and customize an advanced 3-D printer capable of manipulating high performance thermoplastics. The CRP effort will support development needed to harmonize the modeling, prototyping, and manufacturing processes. This project aims to develop the manufacturing capability and commercialization maturity our pacemaker manufacturing partners require.

Award Schedule

  1. 2023
    Solicitation Year

  2. 2024
    Award Year

  3. September 17, 2024
    Award Start Date

  4. August 31, 2026
    Award End Date

Principal Investigator

Name: PETER CABAUY
Phone: (786) 973-7835
Email: peter.cabauy@citylabs.net

Business Contact

Name: PETER CABAUY
Phone: (305) 909-7593
Email: peter.cabauy@citylabs.net

Research Institution

Name: N/A